The UK gene and cell therapy company, Oxford BioMedica PLC, has transformed its business over the past year, becoming debt-free, signing new collaborations with big pharma, and is now progressing a pipeline of preclinical product candidates using its lentivirus gene-delivery platform. Its latest revenue-earner is a $200m tie-up with Juno Therapeutics Inc..
Juno Therapeutics, a Bristol-Myers Squibb Co. subsidiary, has received a non-exclusive license to Oxford Biomedica’s LentiVector platform to use...








